<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814489</url>
  </required_header>
  <id_info>
    <org_study_id>112076</org_study_id>
    <nct_id>NCT00814489</nct_id>
  </id_info>
  <brief_title>Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults</brief_title>
  <official_title>A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2
      formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in
      young adults. Subjects will be vaccinated 2 times in an observer-blind manner with an
      interval of 2 months. The subjects receiving Engerix-B will receive in an open-manner a third
      dose of the vaccine at Month 6. The protocol posting has been updated following a protocol
      amendment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Protocol Posting has been updated following amendment of the Protocol, January 2010. The
      sections impacted are: study design and study endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Any Solicited Local and General Symptoms</measure>
    <time_frame>During a 7-day follow up period after any vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom was defined as occurrence of any solicited local symptom regardless of intensity grade.
Solicited general symptoms assessed were fatigue, gastrointestinal, headache, malaise, myalgia and temperature Any temperature was defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C). For other symptoms: Any = any general symptom reported irrespective of intensity grade and relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AE)</measure>
    <time_frame>During a 30-day (Days 0-29) follow up period after any vaccination</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 to Day 420</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Biochemical Laboratory Abnormalities</measure>
    <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420</time_frame>
    <description>Biochemical parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA) and urea (URE).
Abnormalities reported include values outside the normal ranges. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Hematological Laboratory Abnormalities</measure>
    <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420.</time_frame>
    <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for RBC, WBC High and Low, PLA and HEM. Time points were presented as before (pre) or after (post) doses 1, 2 or 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Hematological Laboratory Abnormalities</measure>
    <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420.</time_frame>
    <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON)), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for BAS, NEU, LYM, EOS and MON. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Protein D (Anti-PD), Pneumolysin (Anti-Ply) and Pneumococcal Histidine Triad D (Anti-PhtD)</measure>
    <time_frame>Days 0, 30, 60, 90, 180 and 420.</time_frame>
    <description>Concentrations were given as Geometric Mean Concentrations (GMCs). The cut-off values were 112 Luminex Units per milliliter (LU/mL) for Anti-PD, 391 LU/mL for Anti-PhtD and 591 LU/mL for Anti-Ply.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</measure>
    <time_frame>Prior to first vaccination (Day 0), at 14 days post vaccination 1 (Day 14) and 2 (Day 74) and at Day 480.</time_frame>
    <description>The mean number was calculated for CD4+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) or pneumolysin toxoid (dPly), identified as producing T-lymphocyte Helper 1 cells (Th1) versus Th2 cytokines (interferon-gamma (IFN-g) and interleukin-13 (IL-13) respectively, as measured by intracellular staining (ICS) on Peripheral Blood Mononuclear Cells (PBMCs). The outcome presents results for cells producing the following combinations:
Th1=IFN-g, Th 2=IL13 and/or IL5 and Th17=IL17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</measure>
    <time_frame>Prior to first vaccination (Day 0), at 14 days post vaccination 1 (Day 14) and 2 (Day 74) and at Day 480.</time_frame>
    <description>The mean number was calculated for CD8+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) and pneumolysin toxoid (dPly) and expressing the following citokine combinations:
C1= at least interleukin 2 (IL2), tumor necrosis factor alpha (TNFa) and/or interferon-gamma (IFNg) and C2= at least interleukin 17 (IL17).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diseases Caused by Streptococcus Pneumoniae and Nontypable Haemophilus Influenzae</condition>
  <condition>Haemophilus Influenzae-Streptococcus Pneumoniae Vaccine</condition>
  <arm_group>
    <arm_group_label>GSK2254233A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2254232A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2231395A</intervention_name>
    <description>Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.</description>
    <arm_group_label>GSK2254233A Group</arm_group_label>
    <arm_group_label>GSK2254232A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.</description>
    <arm_group_label>Engerix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes will comply with the requirements of the
             protocol should be enrolled in the study.

          -  A male or female between, and including, 18 and 40 years of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the subject.

          -  Subject without medical history, clinical finding or laboratory finding, which, in the
             opinion of the investigator, could pose a safety concern or interfere with the
             protocol.

          -  If the subject is female, and of childbearing potential, she agrees to use adequate
             contraception and not become pregnant for the duration of the study.

        Exclusion Criteria:

          -  Pneumonia within 3 years prior to 1st vaccination.

          -  Invasive Pneumococcal Disease within 3 years prior to 1st vaccination.

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period or participation to another pharmaceutical/vaccine study.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of vaccines, with the exception of the influenza
             vaccine which can be administered &gt;14 days prior to or &gt;14 days following vaccine
             doses 1 and 2.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus infection.

          -  History of reaction or hypersensitivity to any component of the vaccine.

          -  Any serious, uncontrolled disease likely to interfere with the study as determined by
             history, physical examination or laboratory screening, as per the judgment of the
             Investigator.

          -  Inflammatory processes such as known chronic infections.

          -  All past or current malignancies and lymphoproliferative disorders.

          -  Laboratory evidence of haematological and biochemical abnormalities.

          -  Acute disease at the time of enrolment/vaccination.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Other conditions that the principal investigator judges may interfere with study
             findings.

          -  Previous vaccination for hepatitis B. As a portion of the subjects will be randomized
             to receive Engerix-B comparator, it is important that all subjects meet Engerix-B
             eligibility criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <results_first_submitted>December 19, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2013</results_first_posted>
  <last_update_submitted>July 18, 2013</last_update_submitted>
  <last_update_submitted_qc>July 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-typable Haemophilus influenzae</keyword>
  <keyword>protein vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK2254233A Group</title>
          <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK2254232A Group</title>
          <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Engerix Group</title>
          <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2254233A Group</title>
          <description>Subjects received 2 doses of GSK2254233A adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2.The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK2254232A Group</title>
          <description>Subjects received 2 doses of non-adjuvanted GSK2254232A Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Engerix Group</title>
          <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="5.91"/>
                    <measurement group_id="B2" value="24.3" spread="3.69"/>
                    <measurement group_id="B3" value="26.6" spread="5.50"/>
                    <measurement group_id="B4" value="25.7" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom was defined as occurrence of any solicited local symptom regardless of intensity grade.
Solicited general symptoms assessed were fatigue, gastrointestinal, headache, malaise, myalgia and temperature Any temperature was defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C). For other symptoms: Any = any general symptom reported irrespective of intensity grade and relationship to vaccination.</description>
        <time_frame>During a 7-day follow up period after any vaccination</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom was defined as occurrence of any solicited local symptom regardless of intensity grade.
Solicited general symptoms assessed were fatigue, gastrointestinal, headache, malaise, myalgia and temperature Any temperature was defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C). For other symptoms: Any = any general symptom reported irrespective of intensity grade and relationship to vaccination.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AE)</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
        <time_frame>During a 30-day (Days 0-29) follow up period after any vaccination</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AE)</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Day 0 to Day 420</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Biochemical Laboratory Abnormalities</title>
        <description>Biochemical parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA) and urea (URE).
Abnormalities reported include values outside the normal ranges. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
        <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Biochemical Laboratory Abnormalities</title>
          <description>Biochemical parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA) and urea (URE).
Abnormalities reported include values outside the normal ranges. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Pre Dose 1 (Day 0) [N=2,2,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not measured at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 2 (Day 180) [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 2 or 3 (Day 300) [N=15,16,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not measured at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 2 or 3 (Day 300) [N=15,16,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not measured at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 2 or 3 (Day 300) [N=15,16,5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not measured at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 2 or 3 (Day 300) [N=15,16,5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>URE, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Protein D (Anti-PD), Pneumolysin (Anti-Ply) and Pneumococcal Histidine Triad D (Anti-PhtD)</title>
        <description>Concentrations were given as Geometric Mean Concentrations (GMCs). The cut-off values were 112 Luminex Units per milliliter (LU/mL) for Anti-PD, 391 LU/mL for Anti-PhtD and 591 LU/mL for Anti-Ply.</description>
        <time_frame>Days 0, 30, 60, 90, 180 and 420.</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Protein D (Anti-PD), Pneumolysin (Anti-Ply) and Pneumococcal Histidine Triad D (Anti-PhtD)</title>
          <description>Concentrations were given as Geometric Mean Concentrations (GMCs). The cut-off values were 112 Luminex Units per milliliter (LU/mL) for Anti-PD, 391 LU/mL for Anti-PhtD and 591 LU/mL for Anti-Ply.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
          <units>LU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD, Day 0 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.4" lower_limit="84.3" upper_limit="195.5"/>
                    <measurement group_id="O2" value="92.3" lower_limit="63.0" upper_limit="135.2"/>
                    <measurement group_id="O3" value="286.9" lower_limit="178.9" upper_limit="460.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Day 30 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314.4" lower_limit="908.5" upper_limit="1901.7"/>
                    <measurement group_id="O2" value="611.8" lower_limit="383.2" upper_limit="976.5"/>
                    <measurement group_id="O3" value="274.9" lower_limit="173.7" upper_limit="435.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Day 60 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="791.3" lower_limit="548.4" upper_limit="1141.7"/>
                    <measurement group_id="O2" value="322.6" lower_limit="198.3" upper_limit="524.8"/>
                    <measurement group_id="O3" value="242.9" lower_limit="149.0" upper_limit="395.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Day 90 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2142.2" lower_limit="1224.5" upper_limit="3747.6"/>
                    <measurement group_id="O2" value="940.9" lower_limit="534.9" upper_limit="1655.0"/>
                    <measurement group_id="O3" value="271.2" lower_limit="173.7" upper_limit="423.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Day 180 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1351.9" lower_limit="711.6" upper_limit="2568.3"/>
                    <measurement group_id="O2" value="416.2" lower_limit="221.8" upper_limit="781.2"/>
                    <measurement group_id="O3" value="242.8" lower_limit="124.8" upper_limit="472.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Day 420 [N=13,16,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="943.4" lower_limit="486.1" upper_limit="1830.8"/>
                    <measurement group_id="O2" value="278.9" lower_limit="152.4" upper_limit="510.2"/>
                    <measurement group_id="O3" value="230.4" lower_limit="104.8" upper_limit="506.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 0 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21128.2" lower_limit="14752.8" upper_limit="30258.6"/>
                    <measurement group_id="O2" value="23633.0" lower_limit="15894.5" upper_limit="35139.1"/>
                    <measurement group_id="O3" value="18313.4" lower_limit="10213.3" upper_limit="32837.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 30 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78690.3" lower_limit="52101.6" upper_limit="118848.0"/>
                    <measurement group_id="O2" value="56628.0" lower_limit="36231.6" upper_limit="88506.4"/>
                    <measurement group_id="O3" value="17881.4" lower_limit="9569.3" upper_limit="33413.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 60 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87193.5" lower_limit="54264.6" upper_limit="140104.3"/>
                    <measurement group_id="O2" value="58419.9" lower_limit="36277.8" upper_limit="94076.3"/>
                    <measurement group_id="O3" value="16396.0" lower_limit="8813.5" upper_limit="30501.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 90 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140774.7" lower_limit="99455.4" upper_limit="199260.3"/>
                    <measurement group_id="O2" value="110714.0" lower_limit="72468.8" upper_limit="169142.8"/>
                    <measurement group_id="O3" value="20184.0" lower_limit="10800.8" upper_limit="37719.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 180 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87320.6" lower_limit="61726.8" upper_limit="123526.3"/>
                    <measurement group_id="O2" value="73013.5" lower_limit="50712.8" upper_limit="105120.8"/>
                    <measurement group_id="O3" value="14537.6" lower_limit="8965.9" upper_limit="23571.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Day 420 [N=13,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52951.7" lower_limit="36919.6" upper_limit="75945.6"/>
                    <measurement group_id="O2" value="52798.1" lower_limit="36302.4" upper_limit="76789.3"/>
                    <measurement group_id="O3" value="14432.0" lower_limit="7243.1" upper_limit="28755.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 0 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14298.4" lower_limit="10112.9" upper_limit="20216.2"/>
                    <measurement group_id="O2" value="14059.5" lower_limit="9488.5" upper_limit="20832.6"/>
                    <measurement group_id="O3" value="17523.6" lower_limit="8747.5" upper_limit="35104.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 30 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170818.2" lower_limit="116569.1" upper_limit="250313.8"/>
                    <measurement group_id="O2" value="106387.7" lower_limit="50833.5" upper_limit="222655.3"/>
                    <measurement group_id="O3" value="20190.6" lower_limit="9177.3" upper_limit="44420.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 60 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161893.6" lower_limit="104981.6" upper_limit="249658.5"/>
                    <measurement group_id="O2" value="87557.0" lower_limit="41715.7" upper_limit="183773.6"/>
                    <measurement group_id="O3" value="18387.8" lower_limit="8281.0" upper_limit="40829.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 90 [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274366.3" lower_limit="206601.5" upper_limit="364357.6"/>
                    <measurement group_id="O2" value="163653.4" lower_limit="92214.9" upper_limit="290434.8"/>
                    <measurement group_id="O3" value="21144.8" lower_limit="10650.6" upper_limit="41978.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 180 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139883.3" lower_limit="103879.1" upper_limit="188366.5"/>
                    <measurement group_id="O2" value="91157.5" lower_limit="53308.3" upper_limit="155880.0"/>
                    <measurement group_id="O3" value="16737.4" lower_limit="7740.2" upper_limit="36193.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Ply, Day 420 [N=13,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92790.4" lower_limit="64466.4" upper_limit="133558.8"/>
                    <measurement group_id="O2" value="59059.5" lower_limit="34604.5" upper_limit="100797.0"/>
                    <measurement group_id="O3" value="15832.6" lower_limit="8103.3" upper_limit="30934.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
        <description>The mean number was calculated for CD4+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) or pneumolysin toxoid (dPly), identified as producing T-lymphocyte Helper 1 cells (Th1) versus Th2 cytokines (interferon-gamma (IFN-g) and interleukin-13 (IL-13) respectively, as measured by intracellular staining (ICS) on Peripheral Blood Mononuclear Cells (PBMCs). The outcome presents results for cells producing the following combinations:
Th1=IFN-g, Th 2=IL13 and/or IL5 and Th17=IL17.</description>
        <time_frame>Prior to first vaccination (Day 0), at 14 days post vaccination 1 (Day 14) and 2 (Day 74) and at Day 480.</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254232A Adjuvanted Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Non-adjuvanted Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
          <description>The mean number was calculated for CD4+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) or pneumolysin toxoid (dPly), identified as producing T-lymphocyte Helper 1 cells (Th1) versus Th2 cytokines (interferon-gamma (IFN-g) and interleukin-13 (IL-13) respectively, as measured by intracellular staining (ICS) on Peripheral Blood Mononuclear Cells (PBMCs). The outcome presents results for cells producing the following combinations:
Th1=IFN-g, Th 2=IL13 and/or IL5 and Th17=IL17.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
          <units>T-cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Th 1, PD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="32.1"/>
                    <measurement group_id="O2" value="6.8" spread="23.5"/>
                    <measurement group_id="O3" value="10.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="42.5"/>
                    <measurement group_id="O2" value="7.7" spread="35.9"/>
                    <measurement group_id="O3" value="7.2" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.6" spread="239.1"/>
                    <measurement group_id="O2" value="37.9" spread="39.9"/>
                    <measurement group_id="O3" value="-6.0" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="38.5"/>
                    <measurement group_id="O2" value="-5.8" spread="23.0"/>
                    <measurement group_id="O3" value="58.7" spread="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PhtD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="30.8"/>
                    <measurement group_id="O2" value="-2.4" spread="21.4"/>
                    <measurement group_id="O3" value="-5.1" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PhtD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.5" spread="263.9"/>
                    <measurement group_id="O2" value="61.6" spread="122.3"/>
                    <measurement group_id="O3" value="6.3" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PhtD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.3" spread="374.0"/>
                    <measurement group_id="O2" value="305.4" spread="294.4"/>
                    <measurement group_id="O3" value="-1.9" spread="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, PhtD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="65.1"/>
                    <measurement group_id="O2" value="16.8" spread="37.4"/>
                    <measurement group_id="O3" value="14.5" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, dPly specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="63.1"/>
                    <measurement group_id="O2" value="27.0" spread="52.6"/>
                    <measurement group_id="O3" value="133.4" spread="209.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, dPly specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.1" spread="199.0"/>
                    <measurement group_id="O2" value="99.3" spread="163.7"/>
                    <measurement group_id="O3" value="92.5" spread="138.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, dPly specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="576.1" spread="348.2"/>
                    <measurement group_id="O2" value="214.8" spread="235.5"/>
                    <measurement group_id="O3" value="76.7" spread="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 1, dPly specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="33.8"/>
                    <measurement group_id="O2" value="0.8" spread="22.1"/>
                    <measurement group_id="O3" value="8.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="287.7"/>
                    <measurement group_id="O2" value="-35.4" spread="328.2"/>
                    <measurement group_id="O3" value="267.3" spread="887.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.1" spread="350.3"/>
                    <measurement group_id="O2" value="40.0" spread="120.7"/>
                    <measurement group_id="O3" value="381.5" spread="1016.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.1" spread="183.0"/>
                    <measurement group_id="O2" value="-42.0" spread="265.8"/>
                    <measurement group_id="O3" value="-43.6" spread="242.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="141.7"/>
                    <measurement group_id="O2" value="13.2" spread="176.1"/>
                    <measurement group_id="O3" value="161.0" spread="394.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PhtD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.4" spread="212.4"/>
                    <measurement group_id="O2" value="-15.6" spread="305.5"/>
                    <measurement group_id="O3" value="238.1" spread="1001.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PhtD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.7" spread="373.4"/>
                    <measurement group_id="O2" value="-47.0" spread="242.2"/>
                    <measurement group_id="O3" value="339.8" spread="1056.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PhtD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-100.8" spread="245.0"/>
                    <measurement group_id="O2" value="-100.9" spread="252.9"/>
                    <measurement group_id="O3" value="-125.6" spread="453.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, PhtD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="139.4"/>
                    <measurement group_id="O2" value="-8.9" spread="103.0"/>
                    <measurement group_id="O3" value="196.2" spread="351.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, dPly specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.3" spread="212.4"/>
                    <measurement group_id="O2" value="-31.2" spread="236.8"/>
                    <measurement group_id="O3" value="256.0" spread="1009.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, dPly specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="236.8"/>
                    <measurement group_id="O2" value="-11.5" spread="128.3"/>
                    <measurement group_id="O3" value="407.2" spread="1227.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, dPly specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="335.7"/>
                    <measurement group_id="O2" value="-15.7" spread="150.3"/>
                    <measurement group_id="O3" value="-126.9" spread="271.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 2, dPly specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="183.4"/>
                    <measurement group_id="O2" value="-14.7" spread="146.5"/>
                    <measurement group_id="O3" value="195.0" spread="414.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PD specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="80.1"/>
                    <measurement group_id="O2" value="17.5" spread="39.7"/>
                    <measurement group_id="O3" value="8.0" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PD specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="58.6"/>
                    <measurement group_id="O2" value="-4.8" spread="42.7"/>
                    <measurement group_id="O3" value="-5.5" spread="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PD specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="65.2"/>
                    <measurement group_id="O2" value="16.2" spread="66.7"/>
                    <measurement group_id="O3" value="-17.0" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="34.1"/>
                    <measurement group_id="O2" value="-4.6" spread="18.7"/>
                    <measurement group_id="O3" value="7.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PhtD specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="76.5"/>
                    <measurement group_id="O2" value="29.5" spread="56.4"/>
                    <measurement group_id="O3" value="12.4" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PhtD specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="94.3"/>
                    <measurement group_id="O2" value="26.1" spread="52.9"/>
                    <measurement group_id="O3" value="2.4" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PhtD specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.8" spread="267.3"/>
                    <measurement group_id="O2" value="114.1" spread="112.3"/>
                    <measurement group_id="O3" value="-10.1" spread="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, PhtD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="44.9"/>
                    <measurement group_id="O2" value="-0.5" spread="28.1"/>
                    <measurement group_id="O3" value="9.8" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, dPly specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="83.0"/>
                    <measurement group_id="O2" value="63.9" spread="79.4"/>
                    <measurement group_id="O3" value="122.1" spread="158.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, dPly specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.1" spread="90.5"/>
                    <measurement group_id="O2" value="95.4" spread="88.9"/>
                    <measurement group_id="O3" value="88.7" spread="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, dPly specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.3" spread="137.3"/>
                    <measurement group_id="O2" value="169.9" spread="125.6"/>
                    <measurement group_id="O3" value="82.3" spread="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th 17, dPly specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="30.7"/>
                    <measurement group_id="O2" value="14.0" spread="26.4"/>
                    <measurement group_id="O3" value="10.2" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
        <description>The mean number was calculated for CD8+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) and pneumolysin toxoid (dPly) and expressing the following citokine combinations:
C1= at least interleukin 2 (IL2), tumor necrosis factor alpha (TNFa) and/or interferon-gamma (IFNg) and C2= at least interleukin 17 (IL17).</description>
        <time_frame>Prior to first vaccination (Day 0), at 14 days post vaccination 1 (Day 14) and 2 (Day 74) and at Day 480.</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
          <description>The mean number was calculated for CD8+ cells stimulated by protein D (PD), pneumococcal histidine triad D (PhtD) and pneumolysin toxoid (dPly) and expressing the following citokine combinations:
C1= at least interleukin 2 (IL2), tumor necrosis factor alpha (TNFa) and/or interferon-gamma (IFNg) and C2= at least interleukin 17 (IL17).</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/comparator and for whom data concerning immunogenicity measures were available.</population>
          <units>T-cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1, PD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.0" spread="166.5"/>
                    <measurement group_id="O2" value="28.0" spread="115.3"/>
                    <measurement group_id="O3" value="3.3" spread="218.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-164.8" spread="247.9"/>
                    <measurement group_id="O2" value="-20.7" spread="109.2"/>
                    <measurement group_id="O3" value="-44.3" spread="224.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-133.3" spread="225.1"/>
                    <measurement group_id="O2" value="7.9" spread="238.8"/>
                    <measurement group_id="O3" value="-67.1" spread="162.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="525.9"/>
                    <measurement group_id="O2" value="68.1" spread="373.3"/>
                    <measurement group_id="O3" value="32.7" spread="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PhtD specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="276.2"/>
                    <measurement group_id="O2" value="53.5" spread="154.8"/>
                    <measurement group_id="O3" value="68.6" spread="271.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PhtD specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.2" spread="277.0"/>
                    <measurement group_id="O2" value="52.9" spread="170.8"/>
                    <measurement group_id="O3" value="-54.3" spread="190.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PhtD specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" spread="269.3"/>
                    <measurement group_id="O2" value="122.5" spread="244.6"/>
                    <measurement group_id="O3" value="-7.4" spread="229.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, PhtD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="517.1"/>
                    <measurement group_id="O2" value="105.6" spread="216.7"/>
                    <measurement group_id="O3" value="84.7" spread="114.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, dPly specific, Day 0 [N=14,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.2" spread="188.5"/>
                    <measurement group_id="O2" value="15.3" spread="129.5"/>
                    <measurement group_id="O3" value="-14.0" spread="192.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, dPly specific, Day 14 [N=13,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="267.1"/>
                    <measurement group_id="O2" value="-29.8" spread="208.2"/>
                    <measurement group_id="O3" value="-104.0" spread="220.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, dPly specific, Day 74 [N=13,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="253.7"/>
                    <measurement group_id="O2" value="41.6" spread="226.5"/>
                    <measurement group_id="O3" value="-88.1" spread="182.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1, dPly specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-219.1" spread="655.0"/>
                    <measurement group_id="O2" value="58.1" spread="230.8"/>
                    <measurement group_id="O3" value="-15.2" spread="114.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PD specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" spread="150.8"/>
                    <measurement group_id="O2" value="74.5" spread="195.7"/>
                    <measurement group_id="O3" value="38.7" spread="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PD specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="105.4"/>
                    <measurement group_id="O2" value="8.2" spread="98.8"/>
                    <measurement group_id="O3" value="-35.2" spread="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PD specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="69.5"/>
                    <measurement group_id="O2" value="-11.9" spread="149.0"/>
                    <measurement group_id="O3" value="21.9" spread="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" spread="91.9"/>
                    <measurement group_id="O2" value="103.5" spread="236.9"/>
                    <measurement group_id="O3" value="78.0" spread="110.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PhtD specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="144.8"/>
                    <measurement group_id="O2" value="56.0" spread="160.6"/>
                    <measurement group_id="O3" value="64.7" spread="106.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PhtD specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="121.9"/>
                    <measurement group_id="O2" value="58.8" spread="130.8"/>
                    <measurement group_id="O3" value="15.7" spread="146.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PhtD specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.3" spread="321.7"/>
                    <measurement group_id="O2" value="20.5" spread="118.6"/>
                    <measurement group_id="O3" value="11.3" spread="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, PhtD specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="60.0"/>
                    <measurement group_id="O2" value="37.8" spread="233.5"/>
                    <measurement group_id="O3" value="109.8" spread="210.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, dPly specific, Day 0 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.8" spread="119.5"/>
                    <measurement group_id="O2" value="31.0" spread="110.0"/>
                    <measurement group_id="O3" value="15.6" spread="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, dPly specific, Day 14 [N=12,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="54.0"/>
                    <measurement group_id="O2" value="66.2" spread="124.1"/>
                    <measurement group_id="O3" value="1.9" spread="145.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, dPly specific, Day 74 [N=12,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="74.0"/>
                    <measurement group_id="O2" value="-30.5" spread="82.2"/>
                    <measurement group_id="O3" value="-17.1" spread="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2, dPly specific, Day 480 [N=11,17,6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="150.5"/>
                    <measurement group_id="O2" value="38.7" spread="174.5"/>
                    <measurement group_id="O3" value="50.3" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Hematological Laboratory Abnormalities</title>
        <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for RBC, WBC High and Low, PLA and HEM. Time points were presented as before (pre) or after (post) doses 1, 2 or 3.</description>
        <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420.</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Hematological Laboratory Abnormalities</title>
          <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for RBC, WBC High and Low, PLA and HEM. Time points were presented as before (pre) or after (post) doses 1, 2 or 3.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC High, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Pre Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Pre Dose 1 (Day 0) [N=2,3,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Hematological Laboratory Abnormalities</title>
        <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON)), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for BAS, NEU, LYM, EOS and MON. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
        <time_frame>During a 7-day follow up period after vaccine dose 1 and 2 and at Days 180, 300 and 420.</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2254233A Group</title>
            <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2254232A Group</title>
            <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix Group</title>
            <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Hematological Laboratory Abnormalities</title>
          <description>Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON)), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges.
This outcome presents results for BAS, NEU, LYM, EOS and MON. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all subjects with at least one study vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BAS, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Pre Dose 1 (Day 0) [N=2,4,0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This parameter was not assessed at Day 0 for subjects in the Engerix Group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 1 (Day 7) [N=15,17,8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 1 (Day 60) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 2 (Day 67) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 2 (Day 180) [N=15,17,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 2 or 3 (Day 300) [N=15,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Post Dose 2 or 3 (Day 420) [N=14,16,7]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected up to Day 420, unsolicited adverse events during a 30-day period after each vaccine dose and solicited symptoms during a 7-day period after each vaccine dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK2254233A Group</title>
          <description>Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK2254232A Group</title>
          <description>Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Engerix Group</title>
          <description>Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

